MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries

Core Insights - MediWound Ltd. announced new clinical data demonstrating that NexoBrid effectively reduces embedded particles in traumatic tattoos caused by abrasion and blast injuries, achieving over 90% reduction in pigmented wound surface [1][4] Clinical Study Findings - The study published in the Journal of Burn Care & Research involved 15 patients with traumatic tattoos, showing a mean pigmented wound area decrease from 37.5% to 2.1% after NexoBrid application, indicating a 92.5% reduction [3][4] - In abrasive injuries, an average of 96% of visible pigments were removed, while in explosive injuries, pigment load was reduced by 84% [4] - The treatment was well tolerated, performed at bedside, with no treatment-related adverse events reported [4] Mechanism and Application - NexoBrid utilizes selective enzymatic action to remove non-viable tissue while preserving viable tissue, providing precision in treating irregular wound depths from blast injuries [5][9] - The application involves a 1–3 mm layer of NexoBrid under occlusion for four hours, followed by gentle scrubbing to reveal a clean wound bed [6] Limitations and Future Research - The study acknowledges limitations such as small sample size and short follow-up, suggesting the need for larger controlled studies to confirm long-term cosmetic outcomes [8] Company Overview - MediWound is a biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair, with NexoBrid approved in over 40 countries for the treatment of thermal burns [11]